Optimal treatment strategy for esophago-gastric junctional cancer

Optimal treatment strategy for esophago-gastric junctional cancer - Optimal treatment strategy for esophago-gastric junctional cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008596

Enrollment

200

Registered

2012-08-01

Start date

2012-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophago-gastric junctional cancer

Interventions

Siewert type I tumor Siewert type II tumor Siewert type III tumor Proximal gastric cancer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) histologically proven esophago-gastric junctional carcinoma (2) clinical solitary tumor (3) age 20-80 years (4) sufficient organ function

Exclusion criteria

Exclusion criteria: (1) synchronous or metachronous malignancy

Design outcomes

Primary

Measure	Time frame
Overall survival and relapse-free survival	—

Countries

Japan

Contacts

Public ContactHiroaki Ito, MD, PhD

Showa University Nothern Yokohama Hospital Digestive Disease Center

h.ito@med.showa-u.ac.jp0459497000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026